AJCP / Meeting AbstrActs v1.1). Sequencing traces were analyzed manually with Mutation Surveyor software. A comprehensive literature search was conducted for reported CYP24A1 genotypes and associated 25OHD/24,25OH2D ratios. Results: Of the 97 patient sera, 22 (23%) had an r25/24>80. Among the 23 sera with CYP24A1 genotyping, 18 (78%) had r25/24 >80, and five (22%) had r25/24 <80. Eight unique pathogenic variations were found across six of 11 exons, with mutations on exons 2 and 9 being most common, in line with previous reports. Cases with r25/24 >80 (range 103-700) were found to harbor two pathogenic mutations (n = 10), homozygous mutations (n = 1), heterozygous mutations (n = 4), and no pathogenic mutations (n = 3). The average 24,25OHD2D concentrations and r25/24 in patients with at least two pathogenic variants were 0.2 ng/mL (IQR 0.1-0.3) and 287 . All other patients had significantly higher 24,25OH2D concentrations (2.3 ng/mL [IQR 1.2-3.8]), and significantly lower r25/24 (14 [IQR 10-21]) (P values < .001, Mann Whitney U test), respectively. Specimens with r25/24 <80 were found to harbor heterozygous pathogenic mutations (n = 3), or no pathogenic variants (n = 2).
Introduction:
Argatroban is a direct, selective thrombin inhibitor. The US Food and Drug Administration licensed its use for patients with or at risk for heparin-induced thrombocytopenia (HIT) undergoing percutaneous coronary intervention. Argatroban and other direct-thrombin inhibitors are being used more often for prophylaxis and treatment of thrombosis in known or suspected HIT. Patients receiving argatroban would be likely to undergo hypercoagulation testing because they are likely to have had a thrombotic event. Thus, we sought to determine if argatroban could interfere with lupus anticoagulant (LA) testing. Methods: To evaluate the effect of argatroban on LA testing, we prospectively and consecutively assessed LA testing for patients when they were receiving argatroban and compared the results with when they were not receiving argatroban to determine the interference of argatroban on these assays. LA testing included the lupus anticoagulant-sensitive activated partial thromboplastin time (PTT-LA) assay, 1:1 mixing, and the confirmatory hexagonal phase (Staclot-LA) assay. We determined the rate of false-positive results of LA tests on ex vivo specimens from patients treated with argatroban. Results: Over a 2.5 year period, 42 patients receiving argatroban were identified at our hospital. Once a patient was determined to be receiving argatroban, an additional plasma specimen before starting argatroban therapy or after discontinuation of argatroban therapy was retrieved. For specimens collected after argatroban was discontinued, a thrombin time was performed and was demonstrated to be normal to ensure that argatroban was no longer present. A total of 100 samples with or without argatroban were available for testing. All patients had a prolonged activated partial thromboplastin time(aPTT) when they were receiving argatroban (mean ± SD: 65.2 ± 23.6 seconds). Interestingly, all argatroban specimens but one showed significant prolongations in the PTT-LA (mean ± SD: 88 ± 32.4 seconds). LA testing was confirmed true-positive in 38% (16/42) of samples from patients not receiving argatroban. Among them, 100% were also positive when on argatroban (mean delta ± SD: off argatroban 16.9 ± 9.6 seconds, on argatroban 30.4 ± 15.4 seconds). For patients without LA, the mean PTT-LA significantly increased when on argatroban (mean ± SD: off argatroban 41.6 ± 12 seconds, on argatroban 87.6 ± 32.1). Among them, all but one (25/26) became false positive when on argatroban (mean delta ± SD: off argatroban 3 ± 2.5 seconds, on argatroban 25.8 ± 17.7 seconds), leading to a 96.1% false-positive rate in confirmatory testing. Hence, only one argatroban specimen was identified as a true-negative for LA testing. These effects were seen even in specimens containing subtherapeutic argatroban levels. Conclusions: Argatroban significantly affects LA testing. The rate of false-positive results in LA testing is unacceptably high in patients receiving argatroban. Clinicians should be advised that LA testing for patients receiving argatroban is not accurate.
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Stroke is a leading cause of serious, long-term disability and the fifth leading cause of death in the United States. Thrombolytic therapy, specifically with intravenous (IV) recombinant tissue plasminogen activator (tPA) can restore cerebral blood flow in some patients with acute ischemic stroke and may lead to improvement or resolution of neurologic defects. The administration of tPA is highly time sensitive, as the medication must be given within 3.0-4.5 hours of symptom onset. In addition to the time limitations,
